Physician profile
Marissa Parrish
NPI 1861186389
$3,403.26
in general payments reported to CMS, 2019-2025
25 companies · $664 in 2025
The $664 reported for 2025 was more than what 78% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $957 · 2024: $1,783 · 2025: $664.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,248 · Education: $155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,247.79 |
| Education | $155.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $948.70 | 2023-2025 | |
| Pfizer INC. | $327.98 | 2023-2025 | |
| Janssen Biotech, INC. | $325.16 | 2023-2025 | Stelara, Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $303.68 | 2023-2025 | Entyvio, Gattex |
| Eisai INC. | $234.85 | 2025 | |
| Madrigal Pharmaceuticals | $189.05 | 2024 | Rezdiffra, Resmetirom |
| Phathom Pharmaceuticals, INC. | $183.81 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $180.73 | 2023-2025 | Omvoh |
| Celltrion USA INC. | $139.82 | 2024-2025 | Zymfentra, Vegzelma |
| Amgen INC. | $136.37 | 2025 | Evenity |
| Celgene Corporation | $94.25 | 2023-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $48.00 | 2023 | Xifaxan |
| Lundbeck LLC | $32.25 | 2025 | Vyepti |
| Merck Sharp & Dohme LLC | $29.04 | 2023 | Dificid |
| Daiichi Sankyo INC. | $27.50 | 2023 | Injectafer |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $24.06 | 2023 | |
| Exact Sciences Corporation | $23.23 | 2023 | Cologuard Collection Kit |
| Intercept Pharmaceuticals, INC. | $21.36 | 2023 | Ocaliva |
| Ardelyx, INC. | $20.86 | 2024 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $20.40 | 2023 | Linzess |
| Aimmune Therapeutics, INC. | $20.13 | 2024 | |
| Grifols USA, LLC | $19.21 | 2025 | Gamunex-C |
| Axonics, INC. | $18.77 | 2023 | Axonics |
| Redhill Biopharma INC. | $17.50 | 2023 | Aemcolo, Talicia |
| Regeneron Healthcare Solutions, INC. | $16.55 | 2023 | Dupixent |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marissa Parrish listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.